Changes in markers of T-cell senescence and exhaustion with atazanavir-, raltegravir-, and darunavir-based initial antiviral therapy: ACTG 5260s

Citation: Kelesidis T, Tran TTT, Stein JH, Brown TT, Moser C, Ribaudo HJ, Dubé MP, Murphy RL, Yang O, Currier JS,  McComsey GA. Changes in markers of T-cell senescence and exhaustion with atazanavir-, raltegravir-, and darunavir-based iinitial antiviral therapy: ACTG 5260s. J Infect Dis. 2016 Sep 1;214(5):748-52. doi: 10.1093/infdis/jiw253. PMID: 27354367. PMCID: PMC4978379.

Access full article:

https://www.ncbi.nlm.nih.gov/pubmed/27354367

It is unclear whether differential roles of CD4(+) versus CD8(+) T-cell senescence/exhaustion and effects of antiretroviral therapy (ART) on these processes may contribute to morbidity in treated human immunodeficiency virus type 1 (HIV) infection. In a prospective 96-week trial, 328 HIV-infected ART-naive participants were randomly assigned to receive tenofovir-emtricitabine plus either atazanavir/ritonavir, darunavir/ritonavir, or raltegravir. Markers of CD4(+) T-cell senescence (ie, the percentage of CD28(-)CD57(+) cells among CD4(+) T cells ) and CD4(+)/CD8(+) T-cell exhaustion (ie, the percentage of PD-1(+) cells among CD4(+)/CD8(+) T cells) decreased after ART. There were no changes in markers of CD8(+) T-cell senescence after ART and no differential changes in all markers in ART groups. Senescent CD4(+) and CD8(+) T cells may have differential roles in HIV pathogenesis.

J Infect Dis, 2016, 214(5):748-52

Categories

CRS
Topics

Clinical Trials

P1077BF: Breastfeeding Version of the PROMISE Study...

1077BF is a randomized strategy trial, which is part of the PROMISE studies (1077BF, 1077FF, P1084s, and 1077HS). The Promoting...

Read More

NWCS 414, Evaluation of a Serum Biosignature for Identifying...

We will address our hypothesis using a case-control study design. We plan to leverage the existing biorepository of...

Read More

ACTIV-2/A5401: Adaptive Platform Treatment for Outpatients...

Rationale: There is an urgent need for a platform to rapidly evaluate therapies in the outpatient setting, to prevent disease...

Read More

A5128: Consent for Use of Stored Patient Specimens for...

The purpose of this study is to obtain informed consent to use stored human biological materials (HBM) (e.g., blood and other...

Read More

A5288: MULTIOCTAVE, Management Using the Latest Technologies...

The study is being done to: test a strategy of using a resistance test to choose anti-HIV drugs. Resistance tests look at the...

Read More